Sale on Manual & Electric Hospital Beds - Starting from 25 September!

Home
Shop
Medical Diagnostic Equipment
Bayer Mark V ProVis (2008)

✓ Certified Professional Seller

Bayer Medical Diagnostic Equipment

Bayer Mark V ProVis (2008)

The Question Is Not Whether It Works. It Is How This Ends.

The Mark V ProVis is the predecessor to Bayer's current angiographic injector, and a 2008 example does the clinical job it was built for perfectly well. What a buyer is actually purchasing is a defined and finite number of remaining years, and the sensible way to buy one is to establish in advance what will end them and what the replacement costs when it does. Medigear.uk prices the exit alongside the equipment.

Sections

Contrast Media Injectors

Categories

Medical Diagnostic Equipment

Condition

Refurbished

Year

2008

Origin

Poland

Seller Type

Certified Professional Seller

CE & ISO Certified

Global Shipping

Supplier: Medigear

There is a straightforward way to think about an eighteen year old injector on a superseded platform, and it is neither of the two positions this equipment usually attracts.

The first unhelpful position is that age settles it. It does not. The clinical function of an angiographic injector is to deliver a set volume of contrast at a set rate under a set pressure limit through a catheter, and a Mark V ProVis in good order performs that function to the same standard as the model that replaced it. The injection is not better on newer hardware. Where the current platform is ahead is in workflow, interface, protocol handling and the recording of injection data, and whether those gaps matter depends entirely on what the receiving department needs rather than on the calendar.

The second unhelpful position is that a working machine at a low price is straightforwardly a bargain. It is not that either, because what is being bought is a remaining service life of unknown length, and three things can end it. The first and hardest is withdrawal of the syringes and connecting tubing, which are proprietary with no approved substitute. When those go, every remaining unit stops at once irrespective of condition. The second is parts for the injector head and console, where the constraint is availability rather than approval. The third is a requirement the department itself imposes later, most commonly around recording injection data into the procedure record or integrating with a replacement imaging system, which a superseded injector may simply be unable to meet.

The mitigating factor, and the reason this platform is worth considering at all, is how widely it was deployed. A platform with a large installed base sustains a market in refurbished parts, independent service and remaining consumable stock long after the manufacturer has moved on, in a way a niche product never does. That is the argument in this unit's favour, and it is an argument about numbers rather than about sentiment. Medigear.uk establishes the current position on each rather than asserting that ubiquity will hold indefinitely, because the whole point is that it does not.

Which leads to the practical recommendation. Buy this with an exit already costed. Establish what the disposables cost per case now and what indication exists about continued supply. Establish what the successor platform costs, and importantly whether the mounting arrangement and any interface work carry across or have to be redone. A department that knows the replacement figure at the point of purchase can treat the price gap as a deliberate deferral of capital spend, which is often a sound decision. A department that does not is simply hoping, and hoping is what makes an inexpensive injector expensive.

The ordinary diligence still applies and matters more on a unit of this age. Electrical safety testing, a planned maintenance and calibration record and a decontamination certificate should accompany it. Delivery accuracy is the entire function of the device, so the calibration record is the evidence for it. The hand controller, cabling, castors and mount components are all replaceable at varying cost and should be assessed individually. One further practical point: a 2008 unit predates Bayer's acquisition of the Medrad business, so it may carry Medrad marking, and a buyer searching for documentation or service under one name and not the other will reach the wrong conclusion about what is available.

Catheter based angiographic and interventional procedures are what this device supports, delivering programmed contrast injections through a selectively placed catheter under pressure limited control. All decisions about contrast agent, volume, rate, pressure and whether an injection is indicated remain entirely with the clinical team, and Medigear.uk supplies configuration and condition detail rather than clinical or pharmacological guidance.

Diagnostic angiography is served to the same standard as by a current platform, since the delivery task has not changed and neither has the physics of it. Where a department's requirement is reliable programmed injection rather than integrated workflow, the specification gap against a newer injector translates into very little clinical difference.

Interventional work is where the gap is more likely to bite, though not through the injection itself. A suite running mixed diagnostic and therapeutic cases places demands on positioning, on coordination with the imaging system and increasingly on the capture of injection data into the procedure record. Those are the areas where a superseded platform shows its age, and a department should establish which of them it actually needs before treating the price as the deciding factor.

Services with constrained capital, second rooms, backup requirements or lower throughput settings are where this platform makes the clearest sense. A costed deferral of capital spend, with the replacement figure known and the horizon understood, is a legitimate procurement decision rather than a compromise. Medigear.uk supplies the disposable, parts and interface position so the decision rests on figures rather than on the price alone.

The Horizon Established Rather Than Ignored

What ends the service life of a superseded injector is disposable withdrawal, parts exhaustion or a requirement the department imposes later. All three are established at purchase so the price can be judged against the years it actually buys.

The Clinical Position Stated Honestly

A unit in good order delivers contrast to the same standard as the platform that replaced it. The successor leads on workflow, interface and data recording rather than on the injection, and saying so lets a buyer weigh the gap against what they need rather than against the year.

Installed Base Treated as the Real Asset

A widely deployed platform sustains refurbished parts, independent service and remaining consumable stock long after the manufacturer moves on, where a niche product does not. That is the argument for this unit, presented as a current position rather than a guarantee.

The Exit Costed at the Point of Purchase

The replacement platform's cost, and whether the mount and interface work carry across or must be redone, are established before the order. A costed deferral of capital spend is a sound decision; an uncosted one is a hope.

Branding Ambiguity Flagged

The line originated with Medrad and Bayer acquired the business after this unit was built, so marking may differ from expectation. A buyer searching under only one name will reach a misleading conclusion about available documentation and service.

Interface Range Checked Against the Suite

Coordination with the imaging system depends on interface, cabling and configuration, and the range a superseded platform can work with is narrower than a current one's. It is confirmed against the installed suite before order.

Calibration Record Weighted Properly

Delivery accuracy is the entire function of the device, so on a unit of this age the maintenance and calibration history carries more weight than the appearance of the machine. It is requested at enquiry.

A Legitimate Route Into Angiographic Capability

For constrained capital, second rooms, backup provision or lower throughput settings, a sound superseded platform at a low price is a reasonable answer rather than a compromise, provided the horizon is known.

High Pressure Angiographic Injection

Built for catheter based selective injection, working in a pressure range distinct from injectors used for peripheral venous administration in cross-sectional imaging.

Year of Manufacture: 2008

Approximately eighteen years old and on a platform since replaced. Both facts put a horizon on the unit rather than a verdict, and the horizon is what gets established.

Platform Position

Predecessor to Bayer's current angiographic injector. The successor path and its cost are identified at purchase rather than at the point of need.

Medrad or Bayer Marking

The line originated with Medrad and the acquisition postdates this build, so marking may vary. Relevant to documentation and service searches rather than to the device itself.

Pressure Limited Delivery

Injection under a set pressure limit, which the lab establishes against the pressure rating of the catheter in use rather than against the device maximum.

Syringe and Flow Configuration

Syringe size, flow range and pressure limit confirmed against the unit rather than quoted from the model family.

Proprietary Disposables

Syringes and connecting tubing are platform specific with no approved substitute. Current availability, cost per case and any indication on continued supply are established before purchase.

Parts and Independent Service Position

Availability of head and console parts and the current independent service route are confirmed, since these set the horizon as much as the consumables do.

Mount as Supplied

Configured on a mobile pedestal with articulated head arm. Whether the arrangement suits the intended room and working position is confirmed against the suite.

Imaging System Interface

Interface, cabling and configuration confirmed against the installed system, noting that the range a superseded platform supports is narrower than a current one's.

Hand Controller and Cabling

Confirmed present and functional, with replacement availability and cost established, since these are commonly damaged or missing on units of this age.

Injection Data Recording

Where a department needs injection data in the procedure record, the platform's capability is confirmed explicitly, as this is among the more common gaps on superseded injectors.

Electrical Safety Testing

Current test results requested with the unit, as required for medical electrical equipment entering clinical service.

Maintenance and Calibration Record

Requested at enquiry and weighted heavily, since delivery accuracy is the function of the device and the record is the evidence for it.

Decontamination Certificate

Requested as a condition of transfer, in line with normal practice for used clinical equipment.

Device Marking and Regulatory Status

Current marking and regulatory position confirmed. This is a medical device subject to device regulation rather than the radiation regime, though the suite it serves carries its own obligations.

This Mark V ProVis was built in 2008 on a platform Bayer has since replaced, and neither fact prevents it doing the job it was made for. Delivering a set contrast volume at a set rate under a set pressure limit is what an angiographic injector does, and a unit in good order performs that to the same standard as the model that succeeded it, with the successor ahead on workflow, interface and data recording rather than on the injection. What a buyer is purchasing is therefore a finite remaining service life, ended not by wear but by withdrawal of the proprietary syringes and tubing, by exhaustion of parts, or by a requirement the department imposes later that a superseded platform cannot meet. The mitigating factor is how widely this family was deployed, since a large installed base sustains parts, independent service and consumable stock long after the manufacturer moves on. The sound way to buy one is with the replacement already costed, so that the price gap represents a deliberate deferral of capital spend rather than a hope. Medigear.uk establishes the disposable position, the parts and service route, the interface range and the successor cost before any offer is made. Contact Medigear.uk for specifications, procurement assistance, or expert consultation.

FAQ

Frequently Asked Questions

Everything buyers need to know about sourcing medical equipment through MediGear.

It is a high pressure contrast injector for catheter based angiographic and interventional procedures, delivering programmed injections under pressure limited control. It is the predecessor to Bayer's current angiographic injector, and this unit was built in 2008.

Possibly either. The line originated with Medrad and Bayer acquired that business after this unit was built, so a 2008 example may carry Medrad marking. It matters practically rather than cosmetically, since searching for documentation or service under only one of the two names gives a misleading picture of what is available.

Yes. Delivering a set contrast volume at a set rate under a set pressure limit is what an angiographic injector does, and a unit in good order performs that to the same standard as the model that replaced it. The successor is ahead on workflow, interface, protocol handling and data recording rather than on the injection itself.

A finite number of remaining years. The condition of the machine is not what determines how many, which is why the sensible purchase establishes the horizon first and treats the price as a figure to be judged against it.

Three things. Withdrawal of the proprietary syringes and tubing, which stops every remaining unit at once regardless of condition. Exhaustion of parts for the head and console. Or a requirement the department imposes later, such as recording injection data into the procedure record or working with a replacement imaging system, which a superseded injector may be unable to meet.

That is the decisive question and it is answered with a current figure rather than an assumption, since the position changes over time and by territory. Medigear.uk establishes present availability, cost per case and any indication about continued supply before an offer is made.

Materially, yes. A widely deployed platform sustains refurbished parts, independent service and remaining consumable stock long after the manufacturer has moved on, in a way a niche product never does. That is the argument for this unit, though it is an argument about current numbers rather than a guarantee, and Medigear.uk states the position as it stands.

It depends on whether the price gap is worth the shorter horizon, and that is only calculable if the replacement figure is known at the outset. Establish what the successor costs, and whether the mount and any interface work carry across or have to be redone. A costed deferral of capital spend is often sound. An uncosted one is not.

That depends on the interface, cabling and configuration rather than on the injector's condition, and a unit that coordinated with one suite does not necessarily drop into another. On a superseded platform the range of systems it can work with is narrower than on a current one, so this is established against the installed suite before order rather than at commissioning.

Electrical safety testing, a planned preventive maintenance and calibration record, and a decontamination certificate. On a unit of this age the calibration record carries more weight rather than less, since delivery accuracy is the whole function of the device. All decisions about contrast agent, volume, rate and pressure remain with the clinical team.